Company intelligence / Profile preview

Amelia Bio

Sydney, New South Wales, Australiaameliabio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Amelia Bio has developed Australia’s only vaginally-inserted probiotic pessary designed to support a healthy vaginal microbiome using clinically studied Lactobacillus strains. The product is science-driven, with input from academic experts in reproductive tract microbiology and infectious diseases, and is currently commercially available in Australia. No clinical trial results are published but the formulation leverages well-studied probiotic strains.

Therapeutic areas: Women's Health
Modalities: Probiotics (vaginally-inserted pessary)
Industry: Biotech

Drug pipeline

1 asset

V-Spot Vaginal Probiotic Pessary

Unknown

Partnerships

Chr. Hansen A/S (supplier/licensor of trademarked probiotic strains GR‑1™ & RC‑14™)University collaborations via scientific advisors

Beyond the preview

Go deeper on Amelia Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amelia Bio.

Explore the full profile